Keith Goldan's most recent trade in Syndax Pharmaceuticals Inc was a trade of 1,226 Common Stock done at an average price of $8.4 . Disclosure was reported to the exchange on July 31, 2025.
| Stock | Client Name | Client Category | Action | Reported to Exchange | Quantity | Post Transaction Holding | Traded % | Avg. Price | Value | Security Type |
|---|---|---|---|---|---|---|---|---|---|---|
| Syndax Pharmaceuticals Inc | Keith Goldan | Chief Financial Officer | Other type of transaction at price $ 8.43 per share. | 31 Jul 2025 | 1,226 | 93,676 (0%) | 0% | 8.4 | 10,335 | Common Stock |
| Syndax Pharmaceuticals Inc | Keith Goldan | Chief Financial Officer | Sale of securities on an exchange or to another person at price $ 9.28 per share. | 16 Jul 2025 | 1,296 | 92,450 (0%) | 0% | 9.3 | 12,033 | Common Stock |
| Syndax Pharmaceuticals Inc | Keith Goldan | Chief Financial Officer | Purchase of securities on an exchange or from another person at price $ 0.00 per share. | 19 May 2025 | 3,000 | 93,746 (0%) | 0% | - | Common Stock | |
| Syndax Pharmaceuticals Inc | Keith Goldan | Chief Financial Officer | Sale of securities on an exchange or to another person at price $ 15.50 per share. | 10 Feb 2025 | 3,777 | 90,746 (0%) | 0% | 15.5 | 58,559 | Common Stock |
| Syndax Pharmaceuticals Inc | Keith Goldan | Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 05 Feb 2025 | 110,500 | 110,500 | - | - | Stock Options (Right to buy) | |
| Syndax Pharmaceuticals Inc | Keith Goldan | Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 05 Feb 2025 | 23,400 | 94,523 (0%) | 0% | 0 | Common Stock | |
| Syndax Pharmaceuticals Inc | Keith Goldan | Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 05 Feb 2025 | 18,500 | 71,123 (0%) | 0% | 0 | Common Stock | |
| Syndax Pharmaceuticals Inc | Keith Goldan | Chief Financial Officer | Purchase of securities on an exchange or from another person at price $ 20.03 per share. | 14 Jun 2024 | 1,250 | 52,623 (0%) | 0% | 20.0 | 25,037 | Common Stock |
| Syndax Pharmaceuticals Inc | Goldan Keith | Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 07 Feb 2024 | 70,000 | 70,000 | - | - | Stock Options (Right to buy) | |
| Syndax Pharmaceuticals Inc | Keith Goldan | Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 07 Feb 2024 | 35,000 | 39,673 (0%) | 0% | 0 | Common Stock | |
| Syndax Pharmaceuticals Inc | Keith Goldan | Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 07 Feb 2024 | 11,700 | 51,373 (0%) | 0% | 0 | Common Stock | |
| Syndax Pharmaceuticals Inc | Keith Goldan | Chief Financial Officer | Other type of transaction at price $ 17.42 per share. | 07 Feb 2024 | 1,183 | 4,673 (0%) | 0% | 17.4 | 20,608 | Common Stock |
| Syndax Pharmaceuticals Inc | Keith Goldan | Chief Financial Officer | Other type of transaction at price $ 18.12 per share. | 07 Feb 2024 | 862 | 3,490 (0%) | 0% | 18.1 | 15,619 | Common Stock |
| Syndax Pharmaceuticals Inc | Keith Goldan | Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 02 Feb 2023 | 110,000 | 110,000 | - | - | Stock Options (Right to buy) | |
| Syndax Pharmaceuticals Inc | Keith Goldan | Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 13 Jun 2022 | 230,000 | 230,000 | - | - | Stock Options (Right to buy) | |
| Syndax Pharmaceuticals Inc | Keith Goldan | Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 13 Jun 2022 | 3,205 | 3,205 (0%) | 0% | 0 | Common Stock | |
| OptiNose Inc | Keith Goldan | Chief Financial Officer | Sale of securities on an exchange or to another person at price $ 2.11 per share. | 16 Mar 2022 | 4,617 | 141,726 (0%) | 0% | 2.1 | 9,742 | Common Stock |
| OptiNose Inc | Keith Goldan | Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 11 Jan 2022 | 85,095 | 85,095 | - | - | Stock Option (Right to Buy) | |
| OptiNose Inc | Keith Goldan | Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 11 Jan 2022 | 66,185 | 66,185 | - | - | Stock Option (Right to Buy) | |
| OptiNose Inc | Keith Goldan | Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 11 Jan 2022 | 56,730 | 146,343 (0%) | 0% | 0 | Common Stock | |
| OptiNose Inc | Keith Goldan | Chief Financial Officer | Sale of securities on an exchange or to another person at price $ 1.64 per share. | 16 Dec 2021 | 580 | 89,613 (0%) | 0% | 1.6 | 951 | Common Stock |
| OptiNose Inc | Keith Goldan | Chief Financial Officer | Sale of securities on an exchange or to another person at price $ 2.79 per share. | 16 Sep 2021 | 578 | 90,193 (0%) | 0% | 2.8 | 1,612 | Common Stock |
| OptiNose Inc | Keith Goldan | Chief Financial Officer | Sale of securities on an exchange or to another person at price $ 3.73 per share. | 17 Jun 2021 | 576 | 90,771 (0%) | 0% | 3.7 | 2,148 | Common Stock |
| OptiNose Inc | Keith Goldan | Chief Financial Officer | Sale of securities on an exchange or to another person at price $ 3.92 per share. | 15 Mar 2021 | 2,304 | 91,347 (0%) | 0% | 3.9 | 9,032 | Common Stock |
| OptiNose Inc | Keith Goldan | Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 04 Mar 2021 | 80,000 | 80,000 | - | - | Stock Option (Right to Buy) | |
| OptiNose Inc | Keith Goldan | Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 04 Mar 2021 | 53,333 | 63,084 (0%) | 0% | 0 | Common Stock | |
| OptiNose Inc | Keith Goldan | Chief Financial Officer | Purchase of securities on an exchange or from another person at price $ 3.90 per share. | 23 Sep 2020 | 2,500 | 9,751 (0%) | 0% | 3.9 | 9,743 | Common Stock |